Autolus Therapeutics (AUTL) Competitors $1.36 -0.05 (-3.21%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. ANIP, APGE, IMCR, KNSA, IRON, SPRY, EWTX, VERA, TVTX, and GPCRShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include ANI Pharmaceuticals (ANIP), Apogee Therapeutics (APGE), Immunocore (IMCR), Kiniksa Pharmaceuticals (KNSA), Disc Medicine (IRON), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Vera Therapeutics (VERA), Travere Therapeutics (TVTX), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. ANI Pharmaceuticals Apogee Therapeutics Immunocore Kiniksa Pharmaceuticals Disc Medicine ARS Pharmaceuticals Edgewise Therapeutics Vera Therapeutics Travere Therapeutics Structure Therapeutics ANI Pharmaceuticals (NASDAQ:ANIP) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking. Do institutionals & insiders hold more shares of ANIP or AUTL? 76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 12.7% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer ANIP or AUTL? ANI Pharmaceuticals received 210 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. However, 68.25% of users gave Autolus Therapeutics an outperform vote while only 64.14% of users gave ANI Pharmaceuticals an outperform vote. CompanyUnderperformOutperformANI PharmaceuticalsOutperform Votes44064.14% Underperform Votes24635.86% Autolus TherapeuticsOutperform Votes23068.25% Underperform Votes10731.75% Which has more risk & volatility, ANIP or AUTL? ANI Pharmaceuticals has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Is ANIP or AUTL more profitable? Autolus Therapeutics has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-1.28% 15.87% 6.88% Autolus Therapeutics N/A -63.65%-36.54% Does the media refer more to ANIP or AUTL? In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 10 mentions for Autolus Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.87 beat Autolus Therapeutics' score of 0.59 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, ANIP or AUTL? ANI Pharmaceuticals has higher revenue and earnings than Autolus Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$614.38M2.48$18.78M-$1.14-61.34Autolus Therapeutics$10.12M35.63-$208.38M-$0.86-1.58 Do analysts prefer ANIP or AUTL? ANI Pharmaceuticals currently has a consensus price target of $80.13, indicating a potential upside of 14.58%. Autolus Therapeutics has a consensus price target of $9.32, indicating a potential upside of 587.82%. Given Autolus Therapeutics' higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryANI Pharmaceuticals beats Autolus Therapeutics on 10 of the 18 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$360.56M$2.90B$5.41B$7.78BDividend YieldN/A1.91%5.44%4.31%P/E Ratio-1.1229.2222.1618.30Price / Sales35.63480.76389.53101.74Price / CashN/A168.6838.2034.62Price / Book2.123.026.654.17Net Income-$208.38M-$72.17M$3.20B$247.50M7 Day Performance-5.24%9.52%5.46%6.15%1 Month Performance-16.36%-6.13%-4.63%-3.38%1 Year Performance-66.79%-19.41%17.54%5.10% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics2.4079 of 5 stars$1.36-3.2%$9.32+587.8%-66.7%$360.56M$10.12M-1.12330Analyst RevisionNews CoverageANIPANI Pharmaceuticals4.1402 of 5 stars$68.00-1.7%$80.13+17.8%+6.4%$1.48B$614.38M-123.64600Analyst DowngradePositive NewsAPGEApogee Therapeutics2.1067 of 5 stars$32.85-0.8%$92.17+180.6%-20.4%$1.48BN/A-13.5791Positive NewsGap DownIMCRImmunocore2.6096 of 5 stars$29.41+3.5%$63.73+116.7%-48.1%$1.47B$310.20M-30.96320News CoveragePositive NewsKNSAKiniksa Pharmaceuticals2.2245 of 5 stars$20.05-0.8%$37.17+85.4%+15.1%$1.46B$423.24M-143.20220Insider TradeIRONDisc Medicine2.193 of 5 stars$42.06-0.3%$93.80+123.0%+69.1%$1.45BN/A-10.5730News CoveragePositive NewsSPRYARS Pharmaceuticals3.1248 of 5 stars$14.32-3.8%$31.00+116.5%+77.2%$1.41B$89.15M-28.0890Positive NewsHigh Trading VolumeEWTXEdgewise Therapeutics2.354 of 5 stars$13.30-1.1%$40.13+201.7%-4.4%$1.39BN/A-8.8760Gap UpVERAVera Therapeutics2.7156 of 5 stars$21.11-0.8%$64.67+206.3%-41.3%$1.35BN/A-8.0940Options VolumePositive NewsTVTXTravere Therapeutics2.6213 of 5 stars$15.11+1.3%$32.08+112.3%+223.5%$1.34B$233.18M-3.69460Analyst ForecastPositive NewsGPCRStructure Therapeutics2.4442 of 5 stars$23.10+6.2%$81.29+251.9%-35.1%$1.32BN/A-31.22136Analyst ForecastNews CoverageHigh Trading Volume Related Companies and Tools Related Companies ANI Pharmaceuticals Competitors Apogee Therapeutics Competitors Immunocore Competitors Kiniksa Pharmaceuticals Competitors Disc Medicine Competitors ARS Pharmaceuticals Competitors Edgewise Therapeutics Competitors Vera Therapeutics Competitors Travere Therapeutics Competitors Structure Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUTL Stock Free AUTL Stock Alerts